Ori Biotech, a producer of cell and gene therapy (CGT) manufacturing technology, has secured over $100 million in an oversubscribed Series B funding round and will use the funds to further expand key personnel across all functions, in order to rapidly transition through pre-commercialisation to the launch of its CGT manufacturing platform.
The Ori Platform
The Ori platform is a manufacturing system that closes, automates, digitises and standardises CGT manufacturing. It will enable therapy developers, contract manufacturers and academic researchers to transition from pre-clinical process discovery through clinical trials to commercial scale. The platform claims to fully automate CGT manufacturing to increase throughput and reproducibility, while improving quality and decreasing costs through hardware, software, data and analytical tools.
Official comments
“Our mission as a company is to enable widespread patient access to life saving cell and gene therapies. One of the biggest obstacles to achieving this is cell and gene therapy manufacturing processes that are too expensive, too highly variable and too low throughput. Our team is focused on the urgent need to enhance the ability of cell and gene therapy developers, CDMOs and Academic Medical Centers to deliver these therapies to as many patients as possible as quickly as possible,” said Jason Foster, CEO of Ori Biotech.
